We enable longer and healthier living through detection and monitoring of serious disease

At Chembio, our mission is to be a leader in the development, manufacture and commercialization of diagnostic solutions. We are dedicated to delivering exceptional products that provide ease of use, and rapid and accurate results at the point-of-care (POC). As a global company, we are committed to innovation and the highest quality standards.

At the core of our commitment is our patented Next Generation DPP® (Dual Path Platform) technology. Our DPP® technology is a breakthrough in POC diagnostics, offering significant advantages over lateral-flow technologies including:

Significantly improved sensitivity

Multiplexing – multiple test results via a single blood sample (e.g., HIV-Syphilis Assay)

Application in a number of indications

Today our DPP® technology is the basis of multiple collaborations with healthcare innovators and leaders worldwide spanning infectious diseases such as HIV, Zika, Ebola, syphilis, malaria and febrile illness, as well as potential new uses in the diagnosis of a specific form of cancer and brain injury (concussion).

Type
Public
HQ
Medford, US
Founded
1986
Employees
155 (est)

Chembio Locations

Medford, US

Chembio Metrics

Chembio Summary

Founding Date

1986

Market capitalization

$82.4 M

Closing share price

$6.85

Chembio Market Value History

Chembio Online Presence

Chembio Company Life

You may also be interested in